Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol-Reference-Cited by-同舟云学术

Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol

Published:2021-11-24 Issue: Volume: Page:
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Ioannou George N.¹²³^ORCID,Lee Sum P.²,Linsley Peter S.⁴,Gersuk Vivian⁴,Yeh Matthew M.²⁵,Chen Yen‐Ying⁵⁶,Peng Yi‐Jen⁵⁷,Dutta Moumita⁸,Mascarinas Gabby⁸,Molla Bruk⁸,Cui Julia Yue⁸,Savard Christopher¹²³

Affiliation:

1. Division of Gastroenterology Department of Medicine Veterans Affairs Puget Sound Health Care System Seattle WA USA

2. Division of Gastroenterology Department of Medicine University of Washington Seattle WA USA

3. Research and Development Veterans Affairs Puget Sound Health Care System Seattle WA USA

4. Systems Immunology Benaroya Research Institute Seattle WA USA

5. Department of Laboratory Medicine and Pathology University of Washington Seattle WA USA

6. Department of Pathology and Laboratory Medicine School of Medicine Taipei Veterans General HospitalNational Yang‐Ming University Taipei Taiwan

7. Department of Pathology Tri‐Service General Hospital National Defense Medical Center Taipei Taiwan

8. Department of Environmental and Occupational Health Sciences University of Washington Seattle WA USA

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

U.S. Department of Veterans Affairs

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1858

Reference38 articles.

1. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

2. A Novel Loss of Function Mutation of PCSK9 Gene in White Subjects With Low-Plasma Low-Density Lipoprotein Cholesterol

3. PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia

4. Molecular biology of PCSK9: its role in LDL metabolism

5. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta‐analysis of randomized controlled trials;Guedeney P;Eur Heart J,2019

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking Cholesterol Metabolism in Metabolic-Associated Steatotic Liver Disease: Molecular Targets and Natural Product Interventions;Pharmaceuticals;2024-08-15

2. A promising therapy for fatty liver disease: PCSK9 inhibitors;Phytomedicine;2024-06

3. Damaging mutations in LXRα uncouple lipogenesis from hepatotoxicity and implicate hepatic cholesterol sensing in human liver health;2024-04-29

4. The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting;Genes;2024-01-21

5. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08